Is Roche Holding (SWX:ROP) Overvalued After CHMP Backed Gazyva For Lupus?
What Does Roche Holding (SWX:ROP) Gain From Gazyva’s New Kidney And Lupus Progress?
What Is Roche Holding (SWX:ROP) Signaling With Its New Alzheimer’s Trial And Tests?
Roche (SWX:ROP) Stock May Be Below Fair Value On FDA Test Clearance
Insider Move: Brandon Cross Exercises Options, Realizing $293K At Roper Technologies
Roper Technologies (ROP) Stock Looks Fully Valued As Cash Flow Comes Into Focus
Roper Technologies increases dividend 10% - its 34th consecutive annual dividend increase
Here’s How Much You Would Have Made Owning Roper Technologies Stock In The Last 20 Years
Roper Technologies Increases Quarterly Dividend From $0.91 To $1.00 Per Share
ETFs Are Net Sellers of Roper Technologies (ROP) on Friday
Roche Holding (SWX:ROP) Expands ADC Pipeline As Late Stage Trial Results Impress
Insider Activity Update: John K Stipancich Executes Options Exercise, Resulting In $569K At Roper Technologies
Roche Holding (SWX:ROP) Could Be 55% Undervalued Following Its Global BAP1 Test Launch
Insider Activity Update: Jason Conley Executes Options Exercise, Resulting In $2.83M At Roper Technologies
Did Earnings Beat Just Shift Roper Technologies (ROP) Investment Narrative?
Roper Technologies (ROP), What Is Behind The Fresh Attention?
Roper Technologies: 3 Key Takeaways for Long-Term Investors
Roper Technologies Analyst Turns Bullish After Q3 Print
JP Morgan Upgrades Roper Technologies to Neutral, Raises Price Target to $490
Can Roche Holding (SWX:ROP) Still Be Cheap After Fresh Trial Wins?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.